BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option ... - Stock Titan
FDA grants Breakthrough Therapy Designation to BridgeBio's infigratinib for achondroplasia, based on PROPEL 2 trial data showing significant AHV increase and body proportionality improvement. PROPEL 3 Phase 3 study is enrolling, aiming for first-in-class oral therapeutic option.
Related Clinical Trials
Reference News
FDA grants Breakthrough Therapy Designation to BridgeBio's infigratinib for children with achondroplasia, based on PROPEL 2 trial data showing significant increase in annualized height velocity and improvement in body proportionality.
FDA grants Breakthrough Therapy to oral infigratinib for children with achondroplasia, based on Phase 2 PROPEL 2 trial results showing significant height velocity increase and body proportionality improvement.
FDA grants breakthrough therapy designation to infigratinib for treating achondroplasia, based on phase 2 data showing significant height velocity increase. BridgeBio Pharma is enrolling for a phase 3 trial.
BridgeBio Pharma's infigratinib receives FDA Breakthrough Therapy Designation for treating achondroplasia, with PROPEL 2 trial showing significant height velocity increase. Ongoing PROPEL 3 study aims for completion by year-end. BridgeBio's diverse pipeline includes other genetic diseases, and recent developments include expedited review for BBP-812 gene therapy and discontinuation of BBP-631 program. Analysts maintain positive ratings, highlighting anticipated sales growth despite stock volatility.
© 2024 Mashup Media, LLC. All rights reserved.
FDA grants Breakthrough Therapy Designation to BridgeBio's infigratinib for achondroplasia, based on PROPEL 2 trial data showing significant AHV increase and body proportionality improvement. PROPEL 3 Phase 3 study is enrolling, aiming for first-in-class oral therapeutic option.